style="font-size:15px;"> 11 11. Edholm K, Ragle N, Rondina MT. Antihrombotic management of atrial fibrillation in the elderly. Med Clin North Am. 2015; 99:417–30.12 12. Sardar P, Chatterjee S, Chaudhari S, Lip GYH. New oral anticoagulants in elderly adults: evidence from a meta‐analysis of randomized trials. J Am Geriatr Soc. 2014; 62:857–864.
13 13. Bai Y, Guo S‐D, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta‐regression analysis. Age and Ageing. 2017; 0:1–9.
14 14. Lip GYH, MD, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018; 49:2933–2944.
15 15. Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub‐analysis from the PREFER in AF (PREvention oF Thromboembolic Events‐European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017; 6(7). pii:e005657. doi:10.1161/JAHA.117.005657.
16 16. Patti G, Pecen L, Lucerna M, et al. Net clinical benefit of non‐vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019; 132:749–757.
17 17. Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011; 130:46–58.
18 18. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population‐based study. J Thromb Haemost. 2007; 5:692–699.
19 19. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community‐based perspective. Thromb Haemost. 2008; 100:780–788.
20 20. Chugh SS, Haymoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837–847.
21 21. Granziera S, Cohen AT, Nante G, et al. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc. 2015; 16:358–6.
22 22. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups, J Thromb Haemost. 2010; 8:2105–2112.
23 23. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia‐induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes. 1995; 44:924–8.
24 24. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (8th ed). Chest. 2008; 133:257S–298S.
25 25. Rosand J, Hylek EM, O’Donnell HC, Greenberg SM. Warfarin‐associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study, Neurology. 2000; 55:947–951.
26 26. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin‐associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study, J Am Geriatr Soc. 2006; 54:1231–1236.
27 27. Thomas IC, Sorrentino MJ. Bleeding risk prediction models in atrial fibrillation. Curr Cardiol Rep. 2014; 16:432.
28 28. Hijazi Z, Oldgren J, Lindbäck J, et al. The novel biomarker‐based ABC (age, biomarkers, clinical history)‐bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387:2302–2311.
29 29. Tavassoli N, Perrin A, Bérard E, et al. Factors associated with undertreatment of atrial fibrillation in geriatric outpatients with Alzheimer disease. Am J Cardiovasc Drugs. 2013; 13:425–433.
30 30. O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015; 36:3258–3264.
31 31. Chang G, Xie Q, Ma L, et al. Accuracy of HAS‐BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta‐analysis. J Thromb Haemost. 2019 Nov 29. doi:10.1111/jth.14692.
32 32. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 1979; 15:319–22.
33 33. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol. 2003; 120:526–8.
34 34. Eccles JT. Control of warfarin therapy in the elderly. Age Ageing. 1975; 4:161–5.
35 35. Schwartz JB, Kane L, Moore K, Wu AHB. Failure of pharmacogenetic‐based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc. 2011; 12:633–638.
36 36. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis Off J Natl Kidney Found. 2010; 56:823–831.
37 37. Dorobantu M, Bogdan S. Unfractionated heparin or low‐molecular‐weight heparin in the elderly. Int J Cardiol. 2016; 222:1084–1090.
38 38. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta‐analysis: low‐molecular‐weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144:673–684.
39 39. Campbell NR, Hull RD, Brant R, et al. Aging and heparin‐related bleeding. Arch Intern Med. 1996; 156:857–860.
40 40. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 00, 1–64.
41 41. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151:297–305.
42 42. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med. 2005; 118:625–635.
43 43. Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370:493–503.
44 44. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta‐analysis. Circulation. 2015; 132:194–204.
45 45. Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Research Reviews. 2019; 49:115–124.
46 46. Caldeira D, Nunes‐Ferreira A, Rodrigues R, et al. Non‐vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta‐analysis and trial sequential analysis. Archives of Gerontology and Geriatrics. 2019; 81:209–214.
47 47. Malik AH, Yandrapalli S, Aronow WS, et al. Meta‐analysis of direct‐acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019; 123:2051−2057.
48 48. Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleve Clin J Med. 2017; 84:35–40.
49 49.
